Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 7A8: Neoadjuvant Nivolumab + Palbociclib + Anastrozole in ER+/HER2- Breast Cancer
NCT04075604Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2019
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of nivolumab in breast cancer, sponsored by Bristol Myers Squibb. Started Oct 2019; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04075604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04075604.